AU2006217650B2 - Use of 2-(2-Nitro-4-Trifluoromethylbenzoyl)-l,3- Cyclohexanedione in the treatment of Parkinson's disease - Google Patents

Use of 2-(2-Nitro-4-Trifluoromethylbenzoyl)-l,3- Cyclohexanedione in the treatment of Parkinson's disease Download PDF

Info

Publication number
AU2006217650B2
AU2006217650B2 AU2006217650A AU2006217650A AU2006217650B2 AU 2006217650 B2 AU2006217650 B2 AU 2006217650B2 AU 2006217650 A AU2006217650 A AU 2006217650A AU 2006217650 A AU2006217650 A AU 2006217650A AU 2006217650 B2 AU2006217650 B2 AU 2006217650B2
Authority
AU
Australia
Prior art keywords
effective amount
pharmaceutically effective
pharmaceutically acceptable
alkyl
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2006217650A
Other languages
English (en)
Other versions
AU2006217650A1 (en
Inventor
John Ernest Doe
Nicholas Crispinian Sturgess
Kim Zachary Travis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Syngenta Ltd
Original Assignee
Syngenta Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syngenta Ltd filed Critical Syngenta Ltd
Publication of AU2006217650A1 publication Critical patent/AU2006217650A1/en
Application granted granted Critical
Publication of AU2006217650B2 publication Critical patent/AU2006217650B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2006217650A 2005-02-28 2006-02-27 Use of 2-(2-Nitro-4-Trifluoromethylbenzoyl)-l,3- Cyclohexanedione in the treatment of Parkinson's disease Ceased AU2006217650B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0504103.3 2005-02-28
GBGB0504103.3A GB0504103D0 (en) 2005-02-28 2005-02-28 Novel method
PCT/GB2006/000684 WO2006090177A1 (en) 2005-02-28 2006-02-27 USE OF 2-(2-NITRO-4-TRIFLUOROMETHYLBENZOYL)-l,3- CYCLOHEXANEDIONE IN THE TREATMENT OF PARKINSON'S DISEASE

Publications (2)

Publication Number Publication Date
AU2006217650A1 AU2006217650A1 (en) 2006-08-31
AU2006217650B2 true AU2006217650B2 (en) 2011-06-09

Family

ID=34430351

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006217650A Ceased AU2006217650B2 (en) 2005-02-28 2006-02-27 Use of 2-(2-Nitro-4-Trifluoromethylbenzoyl)-l,3- Cyclohexanedione in the treatment of Parkinson's disease

Country Status (17)

Country Link
US (1) US20090326072A1 (cg-RX-API-DMAC7.html)
EP (1) EP1853241B1 (cg-RX-API-DMAC7.html)
JP (1) JP2008531665A (cg-RX-API-DMAC7.html)
CN (1) CN101163466B (cg-RX-API-DMAC7.html)
AT (1) ATE524171T1 (cg-RX-API-DMAC7.html)
AU (1) AU2006217650B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0609177A2 (cg-RX-API-DMAC7.html)
CA (1) CA2598517A1 (cg-RX-API-DMAC7.html)
DK (1) DK1853241T3 (cg-RX-API-DMAC7.html)
ES (1) ES2374761T3 (cg-RX-API-DMAC7.html)
GB (1) GB0504103D0 (cg-RX-API-DMAC7.html)
IL (1) IL185410A0 (cg-RX-API-DMAC7.html)
MX (1) MX2007010480A (cg-RX-API-DMAC7.html)
PT (1) PT1853241E (cg-RX-API-DMAC7.html)
RU (1) RU2420272C2 (cg-RX-API-DMAC7.html)
WO (1) WO2006090177A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200707486B (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2748599T3 (es) 2007-08-27 2020-03-17 Dart Neuroscience Cayman Ltd Compuestos terapéuticos de isoxazol
CA2709784A1 (en) * 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
CN102395595A (zh) * 2008-11-06 2012-03-28 生物链接治疗股份有限公司 不宁腿综合症和睡眠障碍的治疗
JP6038132B2 (ja) 2011-06-23 2016-12-07 スウェディッシュ オーファン バイオビトラム インターナショナル アクチエボラグ ニチシノンを含む液体薬学的組成物
CN103622942A (zh) * 2013-11-04 2014-03-12 江苏大学 左旋多巴/卡比多巴复方缓释混悬剂及其制备方法
WO2017017165A1 (en) * 2015-07-29 2017-02-02 Takeda Gmbh Pde4 inhibitor for the treatment of diabetic nephropathy
ITUB20160650A1 (it) 2016-02-11 2017-08-11 Dipharma S A Formulazioni farmaceutiche solide stabili contenenti 2-(2-nitro-4-trifluorometilbenzoil)-1,3-cicloesandione
US9783485B1 (en) 2016-11-30 2017-10-10 Dipharma S.A. Crystalline inhibitor of 4-hydroxyphenylpyruvate dioxygenase, and a process of synthesis and crystallization thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4780127A (en) * 1982-03-25 1988-10-25 Stauffer Chemical Company Certain 2-(substituted benzoyl)-1,3-cyclohexanediones and their use as herbicides
US5092919A (en) * 1991-01-15 1992-03-03 Imperial Chemical Industries Plc Certain 2-(2'-methyl-3',4'-trisubstituted benzoyl)-1,3-cyclohexanediones
AU672361B2 (en) * 1991-06-24 1996-10-03 Swedish Orphan Biovitrum International Ab Use of 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione in the treatment of tyrosinaemia and pharmaceutical compositions
FR2777781B1 (fr) * 1998-04-24 2004-04-09 Rhone Poulenc Rorer Sa Associations riluzole et l-dopa pour le traitement de la maladie de parkinson
US20050288187A1 (en) * 2002-07-03 2005-12-29 Hanauske-Abel Hartmut M Inhibitor development for 4-hydroxyphenylpyruvate dioxygenase, employing tyrosinemia 1 as a model for human diseases mediated by 2-oxoacid utilizing dioxygenases
US20060166972A1 (en) * 2003-07-11 2006-07-27 Conn P J Treatment of movement disorders with a metabotropic glutamate 4 receptor positive allosteric modulator
EP2233136A1 (en) * 2006-08-18 2010-09-29 Syngenta Limited Use of HPPD Inhibitors in the Treatment of Depression and/or Withdrawal Symptoms Associated with Addictive Drugs
CN102395595A (zh) * 2008-11-06 2012-03-28 生物链接治疗股份有限公司 不宁腿综合症和睡眠障碍的治疗

Also Published As

Publication number Publication date
RU2420272C2 (ru) 2011-06-10
CA2598517A1 (en) 2006-08-31
EP1853241A1 (en) 2007-11-14
JP2008531665A (ja) 2008-08-14
WO2006090177A1 (en) 2006-08-31
ES2374761T3 (es) 2012-02-21
CN101163466B (zh) 2011-12-07
BRPI0609177A2 (pt) 2010-02-23
EP1853241B1 (en) 2011-09-14
CN101163466A (zh) 2008-04-16
AU2006217650A1 (en) 2006-08-31
RU2007131934A (ru) 2009-02-27
US20090326072A1 (en) 2009-12-31
ZA200707486B (en) 2009-02-25
PT1853241E (pt) 2012-01-11
IL185410A0 (en) 2008-08-07
DK1853241T3 (da) 2012-01-16
GB0504103D0 (en) 2005-04-06
ATE524171T1 (de) 2011-09-15
HK1110211A1 (en) 2008-07-11
MX2007010480A (es) 2008-02-07

Similar Documents

Publication Publication Date Title
EP3444249B1 (en) Sodium channel blockers, preparation method thereof and use thereof
US20190134056A1 (en) K-ras mutations and antagonists
JP7045985B2 (ja) Ｅｚｈ２阻害剤を用いた髄芽腫の処置方法
KR20150088302A (ko) 피부염 치료법
AU2006217650B2 (en) Use of 2-(2-Nitro-4-Trifluoromethylbenzoyl)-l,3- Cyclohexanedione in the treatment of Parkinson's disease
JP5363636B2 (ja) 新規な塩および医学的使用
Okumura et al. Decrease in tetrahydrobiopterin as a possible cause of nephropathy in type II diabetic rats
JP6343000B2 (ja) オイゲノールを有効成分として含有するアトピー性皮膚炎の予防又は治療用組成物
Gupta et al. Anti-inflammatory activity and pharmacokinetic profile of a new parenteral formulation of nimesulide
AU2006347397A1 (en) Use of HPPD inhibitors in the treatment of depression and/or withdrawal symptoms associated with addictive drugs
HK1110211B (en) Use of 2-(2-nitro-4-trifluoromethylbenzoyl)-1, 3-cyclohexanedione in the treatment of parkinson's disease
KR101733189B1 (ko) 손톱 또는 발톱 성장 촉진용 조성물
HK1142836A (en) Use of hppd inhibitors in the treatment of depression and/or withdrawal symptoms associated with addictive drugs
WO2004082683A1 (ja) 慢性皮膚疾患の治療および／または予防剤
WO2025221944A1 (en) Compositions and methods for treating joint and bone diseases
AU9703601A (en) Method for treating chronic obstructive pulmonary disease
JP2011032267A (ja) １１βＨＳＤ１阻害剤およびその用途

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired